• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MEM
Click for more information
0.00% 0.5¢

MEMPHASYS LIMITED. - Announcements

Market Cap $13.00M  ! watchlist Created with Sketch. Add to my watchlist

Memphasys Limited is an Australia-based reproductive biotechnology company. The Company... Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MEM Results of Meeting30/11/15
MEM Correction to the Chairman's Address to Shareholders30/11/15
MEM Chairman's Address to Shareholders30/11/15
MEM PrIME market update24/11/15
MEM Loan from A GoodallPRICE SENSITIVE18/11/15
MEM Settlement of dispute with former Managing DirectorPRICE SENSITIVE13/11/15
MEM ASX Waivers - Notice of Annual General Meeting30/10/15
MEM Notice of Annual General Meeting/Proxy Form30/10/15
MEM Change in substantial holding09/10/15
MEM Change of Director's Interest Notice09/10/15
MEM Change of Director's Interest Notice09/10/15
MEM Change of Director's Interest Notice09/10/15
MEM Repayment of Marquette Loan09/10/15
MEM Securities Trading Policy30/09/15
MEM 2015 Appendix 4G30/09/15
MEM 2015 Corporate Governance Statement30/09/15
MEM Annual Report30/09/15
MEM Appointment of Andrew Goodall to PrIME Biologics Board10/09/15
MEM Change of Director's Interest Notice08/09/15
MEM Change of Director's Interest Notice08/09/15
MEM Change in substantial holding08/09/15
MEM Cleansing notice04/09/15
MEM Appendix 3B04/09/15
MEM Appendix 4E01/09/15
MEM Half Year AccountsPRICE SENSITIVE01/09/15
MEM New membrane development with University of Melbourne24/08/15
MEM Appointment of Company Secretary11/08/15
MEM Share Purchase Plan Offer Document11/08/15
MEM Investor Presentation11/08/15
MEM START OF IN-VITRO CLINICAL TRIAL AT MONASH IVFPRICE SENSITIVE10/08/15
MEM Security Purchase PlanPRICE SENSITIVE10/08/15
MEM Investor Presentation27/07/15
MEM Proposed Sale of Interest in PrIME Biologics Pte LimitedPRICE SENSITIVE23/07/15
MEM ASIC Investigation of NuSep ConcludedPRICE SENSITIVE09/07/15
MEM Receipt of Short Term Loan and Market UpdatePRICE SENSITIVE29/06/15
MEM Receipt of Funding from Converting Notes Subscriptions05/06/15
MEM Sale of the NuSep Gels Business18/05/15
MEM Change of registry address15/05/15
MEM NuSep Settles Long Standing Fee Dispute21/04/15
MEM Temporary Step Down from the Board of Prime Biologics13/04/15
MEM NuSep Receives Short Term Loan from Singapore CompanyPRICE SENSITIVE10/04/15
MEM Nusep Negotiates Revised Agreement with Newcastle Innovation30/03/15
MEM Half Yearly Report and AccountsPRICE SENSITIVE02/03/15
MEM Change in substantial holding16/02/15
MEM NuSep Investor Presentation10/02/15
MEM Appointment of Auditor09/02/15
MEM Investor Presentation05/02/15
MEM Restated Appendix 3B14/01/15
MEM New Loan Arrangements06/01/15
MEM Ceasing to be a substantial holder05/01/15
MEM Ceasing to be a substantial holder05/01/15
MEM Becoming a substantial holder29/12/14
MEM Change in substantial holding29/12/14
MEM Change of Director's Interest Notice29/12/14
MEM Change of Director's Interest Notice29/12/14
MEM Conversion of Convertible Notes23/12/14
MEM Appendix 3B23/12/14
MEM Appendix 3B22/12/14
MEM Appendix 3B22/12/14
MEM Results of Meeting19/12/14
MEM Chairman's Address to Shareholders19/12/14
MEM Enforceable UndertakingPRICE SENSITIVE18/12/14
MEM R&D Tax RefundPRICE SENSITIVE18/12/14
MEM NuSep Investor Presentation05/12/14
MEM Sale of Minomic Shares02/12/14
MEM Notice of AGM / Proxy Form / Independent Experts Report20/11/14
MEM Further Extension of time to hold Annual General Meeting20/11/14
MEM Supply of Membranes to Prime Biologics Pte LtdPRICE SENSITIVE04/11/14
MEM NuSep signs Heads of Agreement with Minitub GmbHPRICE SENSITIVE04/11/14
MEM Extension of time to hold Annual General Meeting30/10/14
MEM Initial Director's Interest Notice17/10/14
MEM Director Appointment17/10/14
MEM Market UpdatePRICE SENSITIVE08/10/14
MEM Annual Financial Report01/10/14
MEM Final Director's Interest Notice11/09/14
MEM Initial Director's Interest Notice10/09/14
MEM Director Appointment10/09/14
MEM Appendix 4EPRICE SENSITIVE01/09/14
MEM First Completion of Investment Transaction19/06/14
MEMPayment Renegotiation for Singapore Processing FacilityPRICE SENSITIVE05/06/14
MEMNuSep Investor Presentation28/05/14
MEMResponse to ASX Appendix 3Z Letter22/05/14
MEMChange in substantial holding14/05/14
MEMChange in substantial holding14/05/14
MEMFinal Director's Interest Notice13/05/14
MEMOff Market Share TransactionPRICE SENSITIVE12/05/14
MEMInvestment Transaction For PrIME Biologics Private LimitedPRICE SENSITIVE09/05/14
MEMTrading HaltPRICE SENSITIVE07/05/14
MEMDirector Resignation28/04/14
MEMBecoming a substantial holder10/03/14
MEMLoan FacilitiesPRICE SENSITIVE03/03/14
MEMHalf Yearly Report and AccountsPRICE SENSITIVE28/02/14
MEMAppendix 3B and Cleansing Notice19/02/14
MEMPlacementPRICE SENSITIVE19/02/14
MEMChange in Chief Executive OfficerPRICE SENSITIVE11/02/14
MEMCompany Secretary Change11/02/14
MEMPrIME Update29/01/14
MEMProposed Issue of Share OptionsPRICE SENSITIVE24/01/14
MEMNuSep Working Capital AdvancePRICE SENSITIVE20/01/14
MEMIncrease in Director Holdings31/12/13
MEM Results of Meeting
30/11/15
MEM Correction to the Chairman's Address to Shareholders
30/11/15
MEM Chairman's Address to Shareholders
30/11/15
MEM PrIME market update
24/11/15
MEM Loan from A Goodall
18/11/15PRICE SENSITIVE
MEM Settlement of dispute with former Managing Director
13/11/15PRICE SENSITIVE
MEM ASX Waivers - Notice of Annual General Meeting
30/10/15
MEM Notice of Annual General Meeting/Proxy Form
30/10/15
MEM Change in substantial holding
09/10/15
MEM Change of Director's Interest Notice
09/10/15
MEM Change of Director's Interest Notice
09/10/15
MEM Change of Director's Interest Notice
09/10/15
MEM Repayment of Marquette Loan
09/10/15
MEM Securities Trading Policy
30/09/15
MEM 2015 Appendix 4G
30/09/15
MEM 2015 Corporate Governance Statement
30/09/15
MEM Annual Report
30/09/15
MEM Appointment of Andrew Goodall to PrIME Biologics Board
10/09/15
MEM Change of Director's Interest Notice
08/09/15
MEM Change of Director's Interest Notice
08/09/15
MEM Change in substantial holding
08/09/15
MEM Cleansing notice
04/09/15
MEM Appendix 3B
04/09/15
MEM Appendix 4E
01/09/15
MEM Half Year Accounts
01/09/15PRICE SENSITIVE
MEM New membrane development with University of Melbourne
24/08/15
MEM Appointment of Company Secretary
11/08/15
MEM Share Purchase Plan Offer Document
11/08/15
MEM Investor Presentation
11/08/15
MEM START OF IN-VITRO CLINICAL TRIAL AT MONASH IVF
10/08/15PRICE SENSITIVE
MEM Security Purchase Plan
10/08/15PRICE SENSITIVE
MEM Investor Presentation
27/07/15
MEM Proposed Sale of Interest in PrIME Biologics Pte Limited
23/07/15PRICE SENSITIVE
MEM ASIC Investigation of NuSep Concluded
09/07/15PRICE SENSITIVE
MEM Receipt of Short Term Loan and Market Update
29/06/15PRICE SENSITIVE
MEM Receipt of Funding from Converting Notes Subscriptions
05/06/15
MEM Sale of the NuSep Gels Business
18/05/15
MEM Change of registry address
15/05/15
MEM NuSep Settles Long Standing Fee Dispute
21/04/15
MEM Temporary Step Down from the Board of Prime Biologics
13/04/15
MEM NuSep Receives Short Term Loan from Singapore Company
10/04/15PRICE SENSITIVE
MEM Nusep Negotiates Revised Agreement with Newcastle Innovation
30/03/15
MEM Half Yearly Report and Accounts
02/03/15PRICE SENSITIVE
MEM Change in substantial holding
16/02/15
MEM NuSep Investor Presentation
10/02/15
MEM Appointment of Auditor
09/02/15
MEM Investor Presentation
05/02/15
MEM Restated Appendix 3B
14/01/15
MEM New Loan Arrangements
06/01/15
MEM Ceasing to be a substantial holder
05/01/15
MEM Ceasing to be a substantial holder
05/01/15
MEM Becoming a substantial holder
29/12/14
MEM Change in substantial holding
29/12/14
MEM Change of Director's Interest Notice
29/12/14
MEM Change of Director's Interest Notice
29/12/14
MEM Conversion of Convertible Notes
23/12/14
MEM Appendix 3B
23/12/14
MEM Appendix 3B
22/12/14
MEM Appendix 3B
22/12/14
MEM Results of Meeting
19/12/14
MEM Chairman's Address to Shareholders
19/12/14
MEM Enforceable Undertaking
18/12/14PRICE SENSITIVE
MEM R&D Tax Refund
18/12/14PRICE SENSITIVE
MEM NuSep Investor Presentation
05/12/14
MEM Sale of Minomic Shares
02/12/14
MEM Notice of AGM / Proxy Form / Independent Experts Report
20/11/14
MEM Further Extension of time to hold Annual General Meeting
20/11/14
MEM Supply of Membranes to Prime Biologics Pte Ltd
04/11/14PRICE SENSITIVE
MEM NuSep signs Heads of Agreement with Minitub GmbH
04/11/14PRICE SENSITIVE
MEM Extension of time to hold Annual General Meeting
30/10/14
MEM Initial Director's Interest Notice
17/10/14
MEM Director Appointment
17/10/14
MEM Market Update
08/10/14PRICE SENSITIVE
MEM Annual Financial Report
01/10/14
MEM Final Director's Interest Notice
11/09/14
MEM Initial Director's Interest Notice
10/09/14
MEM Director Appointment
10/09/14
MEM Appendix 4E
01/09/14PRICE SENSITIVE
MEM First Completion of Investment Transaction
19/06/14
MEMPayment Renegotiation for Singapore Processing Facility
05/06/14PRICE SENSITIVE
MEMNuSep Investor Presentation
28/05/14
MEMResponse to ASX Appendix 3Z Letter
22/05/14
MEMChange in substantial holding
14/05/14
MEMChange in substantial holding
14/05/14
MEMFinal Director's Interest Notice
13/05/14
MEMOff Market Share Transaction
12/05/14PRICE SENSITIVE
MEMInvestment Transaction For PrIME Biologics Private Limited
09/05/14PRICE SENSITIVE
MEMTrading Halt
07/05/14PRICE SENSITIVE
MEMDirector Resignation
28/04/14
MEMBecoming a substantial holder
10/03/14
MEMLoan Facilities
03/03/14PRICE SENSITIVE
MEMHalf Yearly Report and Accounts
28/02/14PRICE SENSITIVE
MEMAppendix 3B and Cleansing Notice
19/02/14
MEMPlacement
19/02/14PRICE SENSITIVE
MEMChange in Chief Executive Officer
11/02/14PRICE SENSITIVE
MEMCompany Secretary Change
11/02/14
MEMPrIME Update
29/01/14
MEMProposed Issue of Share Options
24/01/14PRICE SENSITIVE
MEMNuSep Working Capital Advance
20/01/14PRICE SENSITIVE
MEMIncrease in Director Holdings
31/12/13
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $13.00M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
7 6639600 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 11066843 9
View Market Depth
Last trade - 07.01am 29/11/2024 (20 minute delay) ?
MEM (ASX) Chart

Top Stories

Ricciardo speeds to 83% antimony recovery for Warriedar

Warriedar Resources Ltd has achieved strong recoveries and a marketable antimony product from its Ricciardo deposit in WA
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.